
Opinion|Videos|June 28, 2024
Biologics Utilization Impacting US Health Care Spending
Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST, and Chad Cannon, PharmD, BCCCP, open a panel discussion highlighting specialty biologics and navigating challenges for biosimilar uptake.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- How significant is the impact of specialty medications, particularly biologics, on current US health care spending?
- What have been the major challenges and successes in reducing health care costs through the use of biosimilars?
- Briefly, what is hindering biosimilar uptake?
- Where have biosimilars been successful?
- What are some strategies for successful biosimilar adoption?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
House Republicans Block Vote on ACA Subsidy Extension
2
Zasocitinib Hits Phase 3 End Points in Plaque Psoriasis
3
ICYMI: Highlights From the 2025 ASPC Congress on CVD Prevention
4
Higher BMI, IBD Linked to Hidradenitis Suppurativa Risk via Mendelian Randomization
5







































